alexa Emerging Role Of Metabolic Response Measured With 18F-FDG PET Towards Personalized Radiotherapy Or Radio Chemotherapy In Lung Cancer | 9759
ISSN: 2161-1025

Translational Medicine
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

2nd International Conference on Translational & Personalized Medicine

Noah C. Choi
Accepted Abstracts: Transl Med
DOI: 10.4172/2161-1025.S1.010
Abstract
Lung cancer is the leading cause of cancer death. Yet, current standard radiotherapy is still associated with local failure rates of 40% even with cisplatin-based concurrent chemotherapy in inoperable stage IIIA and IIIB non-small-cell lung cancer (NSCLC). Thus, a large number of patients still have residual cancer at the end of standard-dose radiotherapy and chemotherapy, but there are no means of predicting which ones. The goal of this research was to determine a bioimaging metabolic biomarker (BMB) capable of detecting residual cancer soon after standard radiotherapy and guiding supplementary therapy in timely fashion for patients with residual cancer. Critical elements of BMB necessary for personalized radiotherapy were determined. They are: (1). Earliest time point for attaining the maximum metabolic response (MRglc-MMR) with 18F-FDG PET after radiotherapy or radiochemotherapy, (2). The association between residual MRglc representing MRglc-MMR at 10-12 days (S2) after therapy and tumor control probability (TCP) at 12 months that was found to be an inverse dose response relationship. (3). The optimum cut-off values for identifying patients with high risk for residual cancer were determined by correlating different levels of MRglc- MMR at S2 with their corresponding TCP, sensitivity and specificity. If a cut-off value of MRglc ≤0.071 μmol/min/g by simplified kinetic method (SKM) or ≤1.45 of SUVmax is chosen, it offers a sensitivity of 100 % and a specificity of 63 %, meaning that these values will identify all patients with residual cancer for salvage therapy while it also includes 37 % of patients in whom complete tumor control has already been achieved. This is the first report on the potential utility of cut-off values of MRglc-MMR at S2 for developing personalized therapy in patients with lung cancer.
Biography
Noah C. Choi is professor of radiation oncology at Harvard Medical School and director of thoracic radiation oncology and distinguished scholar in thoracic oncology at Massachusetts General Hospital Cancer Center. His main research topics are: Bioimaging in radiotherapy for Lung Cancer supported by NIH/NIBIB grant R01 EB002907 and proton therapy for lung cancer. He published more than 130 papers in reputed journals.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri and Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

streamtajm

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version